Bernstein noted that the LAG3 melanoma study has no enrollment floor or cap on PDL1 expression, though Regeneron powered the study assuming pembrolizumab outperformance compared to the RELATIVITY-047 ...

Good morning, everybody. My name is Alex Hammond, and I'm the senior biopharma analyst here at Wolfe Research. Thanks for joining. So with me, I have Regeneron. I have Justin Holko, Global Oncology, ...

Panelists discuss long-term efficacy and safety outcomes from pivotal studies evaluating dual immune checkpoint inhibition in advanced melanoma. This discussion focuses on the extended follow-up ...

OVER THE PAST decade, breakthroughs in cancer immunology have transformed the outlook for patients undergoing advanced melanoma therapy. Immune checkpoint inhibitors (ICIs) have become a cornerstone ...

Planets orbiting dead stars known as white dwarfs might be able to remain habitable thanks to general relativity subtly altering their motion. When stars like our sun run out of fuel, they expand and ...

CHECKPOINT blockade has transformed outcomes in metastatic melanoma. Combinations of PD-1 and CTLA-4 inhibitors, such as nivolumab plus ipilimumab, have achieved long-term survival rates exceeding ...